Abstract
Activated Leukocyte Cell Adhesion Molecule (ALCAM, also called CD 166, MEMD) as cell surface immunoglobulin is reported as prognostic marker in breast cancer, but its predictive value has not yet been evaluated. We have analyzed ALCAM protein expression by Western Blot analysis (n = 160) and mRNA expression by cDNA microarray analysis (n = 162) in primary mammary carcinomas. Both expression results were obtained in 133 cases, showing a strong positive correlation between protein expression and mRNA expression (P < 0.001). Neither ALCAM protein nor mRNA expression are correlated to histological type, grading, stage or age of patient. However, ALCAM protein expression correlates positively with estrogen receptor status (ER) (P = 0.025). A stratified subgroup analysis showed positive correlation of high ALCAM mRNA expression with longer overall survival (OAS; P = 0.0012) in patients treated with adjuvant chemotherapy (n = 100). In contrast, patients with high ALCAM mRNA expression who did not receive chemotherapy tended to have a worse prognosis. Similar but weaker correlations were found regarding ALCAM protein expression data. The predictive impact of ALCAM mRNA expression in chemotherapy treated patients was corroborated by multivariate Cox regression analysis also including histopathological markers (P = 0.001 for OAS). Our overall results reveal that high ALCAM expression levels in primary tumors might be a suitable marker for prediction of the response to adjuvant chemotherapy in breast cancer.
Similar content being viewed by others
References
Rampaul RS, Pinder SE, Elstopn CW et al (2001) Prognostic and predictive factors in primary breast cancer and their role patient management. The Nottingham Breast Team. Eur J Surg Oncol 27:229–238
van Kempen LCLT, Nelissen JMDT, Degen WJG et al (2001) Molecular basis for the homophilic activated leukocyte cell adhesion molecule (ALCAM)-ALCAM interaction. J Biol Chem 176:25783–25790
Swart GWM (2002) Activated leukocyte cell adhesion molecule (CD166/ALCAM): developmental and mechanistic aspects of cell clustering and cell migration. Eur J Cell Biol 81:313–321
Bruder SP, Ricalton NS, Boynton RE et al (1998) Mesenchylam stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J Bone Mineral Res 13:655–663
Bowen MA, Aruffo A (1999) Adhesion molecules, their receptors, and their regulation: analysis of CD6-activated leukocyte adhesion molecule (ALCAM/CD166) interactions. Transplant Proc 31:795–796
Fujiwara H, Tatsumi K, Kosaka K et al (2003) Human blastocysts and endometrial epithelial cells express activated leukocyte cell adhesion molecule (ALCAM/CD166). J Clin Endocrinol Metab 88:3437–3443
Ohneda O, Ohneda K, Arai F et al (2001) ALCAM (CD166): its role in hematopoietic and endothelial development. Blood 98:2134–2142
King J, Ofori-Acquah S, Stevens T et al (2004) Potential role for activated leukocyte cell adhesion molecule and neural cadherin in metastasis to the lung microcirculation. Chest 125:150S–151S
Swart GWM, Lunter PC, van Kilsdonk JWJ et al (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166): signaling at the divide of melanoma cell clustering and cell migration? Cancer Met Rev 24:223–236
Kristiansen G, Pilarsky C, Wissmann C et al (2003) ALCAM/CD166 is up-regulated in low-grade prostate cancer and progressively lost in high-grade lesions. Prostate 54:34–43
Weichert W, Knosel T, Bellach J et al (2004) ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 57:1160–1164
Verma A, Shukla NK, Deo SV et al (2005) MEMD/ALCAM: a potential marker for tumor invasion and nodal metastasis in esophageal squamous cell carcinoma. Oncology 68:462–470
King JA, Ofori-Acquah SF, Stevens T et al (2004) Activated leukocyte cell adhesion molecule in breast cancer: prognostic indicator. Breast Cancer Res 6:R478–487
Jezierska A, Olszewski WP, Pietruszkiewicz J et al (2006) Activated cell adhesion molecule (ALCAM) is associated with suppression of breast cancer cells invasion. Med Sci Monit 12:BR245–BR256
Burkhardt M, Mayordomo E, Winzer K-J et al (2006) Cytoplasmic overexpression of ALCAM is prognostic of disease progression in breast cancer. J Clin Pathol 59:403–409
Bamberger A-M, Methner C, Lisboa BW et al (1999) Expression pattern of the AP-1 family in breast cancer: association of fosB expression with a well-differentiated, receptor-positive phenotype. Int J Cancer 84:553–558
Dalerba P, Dylla SJ, Park I-K et al (2007) Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci 104:10158–10163
Jezierska A, Matysiak W, Motyl T (2006) ALCAM/CD166 protects breast cancer cells against apoptosis and autophagy. Med Sci Monit 12:BR263–BR273
Paik S, Tang G, Shak S et al (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726–3734
Chang JC, Wooten EC, Tsimelzon A et al (2003) Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 363:362–369
Ayers M, Symmans WF, Stec J et al (2004) Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin and cyclophoyphamide chemotherapy in breast cancer. J Clin Oncol 22:2284–2293
Blaheta RA, Daher FH, Michaelis M et al (2006) Chemoresistance induces enhanced adhesion and transendothelial penetration of neuroblastoma cells by down-regulating NCAM surface expression. BMC Cancer 6:294
Kajiyama H, Shibata K, Terauchi M et al (2007) Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol 31(2):277–283
Lunter PC, van Kilsdonk JW, van Beek H et al (2005) Activated leukocyte cell adhesion molecule (ALCAM/CD166/MEMD), a novel actor in invasive growth, controls matrix metalloproteinase activity. Cancer Res 65:8801–8808
Acknowledgements
The authors thank Katrin Beck for excellent technical assistance as well as Ewa Laczynska and Alexandra Braune for their help with the acquisition of follow-up data. In addition, we are grateful to Prof. Dr. K. Wegscheider, Department of Medical Biometry and Epidemiology, University Medical Center Hamburg-Eppendorf, and Dr. Christian von Törne (Siemens Medical Solutions Diagnostics GmbH) for their help with the statistical evaluation of the data. This work was partly supported by a grant from the Deutsche Krebshilfe, No. 106110.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ihnen, M., Müller, V., Wirtz, R.M. et al. Predictive impact of activated leukocyte cell adhesion molecule (ALCAM/CD166) in breast cancer. Breast Cancer Res Treat 112, 419–427 (2008). https://doi.org/10.1007/s10549-007-9879-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10549-007-9879-y